Showing 1231-1240 of 3103 results for "".
- Applying the 2024 McDonald Diagnostic Criteria Effective for Identifying Prodromal MS in Real-World Studyhttps://practicalneurology.com/news/applying-the-2024-mcdonald-diagnostic-criteria-effective-for-identifying-prodromal-ms-in-real-world-study/2473799/Applying the 2024 McDonald diagnostic criteria for multiple sclerosis (MS) was effective in identifying individuals with prodromal MS, according to data presented at the Americas Committee for T
- First Guidelines for De-escalating and Discontinuing MS Therapies Releasedhttps://practicalneurology.com/news/first-guidelines-for-de-escalating-and-discontinuing-ms-therapies-released/2475069/A panel of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) has developed the first comprehensive guidelines for de-escalating and discontinuing disease-modifying therapies (DMTs) in individuals diagnosed with multiple sclerosis (MS). The guidelines, published in
- Researchers Find Association Between Dysregulation of Three Genes and MShttps://practicalneurology.com/news/researchers-find-association-between-dysregulation-of-three-genes-and-ms/2470082/New research published in the Annals of Clinical and Translational Neurology has identified dysregulation in three specific genes along with their expressed proteins that may be associated with multiple sclerosis (MS). The three genes were SHMT1, FAM120B, and ICA1L. As part of
- Investigational MS Treatment Diroximel Fumarate Has Improved Gastrointestinal Tolerabilityhttps://practicalneurology.com/news/investigational-ms-treatment-diroximel-fumarate-has-improved-gastrointestinal-tolerability/2468982/Topline results from the EVOLVE-MS-2 study (NCT02634307), of diroximel fumarate (ALKS8700, BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) have been announced. Pa
- Diroximel Fumarate Treatment of Relapsing MS Has Improved Gastrointestinal Tolerability and Improved Quality of Lifehttps://practicalneurology.com/news/diroximel-fumarate-treatment-of-relapsing-ms-has-improved-gastrointestinal-tolerability-and-improved-quality-of-life/2469379/In EVOLVE-MS-2 (NCT03093324) trial of diroximel fumarate (Vumerity; Biogen, Cambridge, MA), recently approved for the treatment of relapsing forms of multiple sclerosis (MS), had significantly more gastrointestinal (GI) tolerability th
- Paramagnetic Rim Lesions Predict Conversion to Clinical MS in Radiologically Isolated Syndromehttps://practicalneurology.com/news/paramagnetic-rim-lesions-predict-conversion-to-clinical-ms-in-radiologically-isolated-syndrome/2485881/In a prospective multicenter cohort study published in JAMA Neurology, paramagnetic rim lesions (PRLs) detected on susceptibility-sensitive MRI in individuals with radiologically isolated syndrome (RIS) were associated with increased risk of developing clinical multiple sclerosis (MS). A
- Risk of Adult-Onset MS Associated with Maternal Pregnancy Outcomes in Studyhttps://practicalneurology.com/news/risk-of-adult-onset-ms-associated-with-maternal-pregnancy-outcomes-in-study/2485407/Individuals born large for their gestational age or exposed to maternal diabetes during pregnancy may have an increased risk for developing multiple sclerosis (MS) in adulthood, according to findings from a population-based cohort study published in JAMA Neurology. In contrast, individua
- New Consensus Statement Aims to Refine PIRA Assessment in MShttps://practicalneurology.com/news/new-consensus-statement-aims-to-refine-pira-assessment-in-ms/2483550/Although Progression Independent of Relapse Activity (PIRA) is recognized as a key driver of disability accumulation in multiple sclerosis (MS), its clinical utility has been limited by a lack of consensus definition in the field and overreliance on the Expanded Disability Status Scale (EDSS). In
- Anti-CD20 Therapies Outperform Platform DMTs in Pediatric MShttps://practicalneurology.com/news/high-efficacy-anti-cd20-vs-platform-therapies-in-prepubertal-pediatric-ms/2483537/Anti-CD20 therapies were associated with superior outcomes compared with traditional platform disease-modifying treatments (DMTs) for children with prepubertal-onset multiple sclerosis (MS) according to study results presented at the 41st Congress of the European Committee for Treatment and Resea
- Paramagnetic Rim Lesions May Support Diagnosis in People with Suspected MShttps://practicalneurology.com/news/paramagnetic-rim-lesions-show-diagnostic-value-in-multiple-sclerosis-clinics/2483418/Paramagnetic rim lesions (PRLs), which are visible on susceptibility-based MRI, may serve as a useful diagnostic marker in people undergoing evaluation for multiple sclerosis (MS), according to a new study published in Neurology. The presence of PRLs was associated with increased diagnos